Pluvicto's Reach Nearly Doubles Overnight

FDA clears earlier use of the radioligand therapy, widening access across PSMA-positive metastatic disease.

7 Aug 2026

Approval decisions rarely double a drug's addressable population in one stroke. Pluvicto's just did. The FDA has cleared the radioligand therapy for use earlier in the prostate cancer treatment journey, in combination with an androgen receptor pathway inhibitor, for patients with metastatic hormone sensitive prostate cancer.

The clearance extends Pluvicto's reach across all stages of PSMA positive metastatic disease for the first time, nearly doubling the number of eligible patients. The clearance rests on the Phase III PSMAddition trial, in which Pluvicto combined with standard of care cut the risk of progression or death by 28 percent versus standard of care alone.

An updated analysis pushed that figure further, to a 33 percent reduction, alongside a positive overall survival trend as data continue to mature. The scale of the opportunity is considerable.

More than 186,000 men are diagnosed with metastatic hormone sensitive prostate cancer globally each year, and roughly half progress to castration resistant disease within 20 months. That pattern has driven demand for earlier, more targeted intervention.

Michael Morris of Memorial Sloan Kettering Cancer Center, a principal investigator on the trial, said the approval reflects growing recognition that earlier treatment intensification matters. Gina Carithers, chief executive of the Prostate Cancer Foundation, described the milestone as redefining prostate cancer care by giving men a precision option from the earliest days of a metastatic diagnosis.

Novartis says it now operates five radioligand therapy manufacturing sites in the United States, either operational or under construction. That gives the company capacity to deliver Pluvicto to treatment sites within five days.

That manufacturing footprint now faces a genuine test. Whether infrastructure investments made over recent years can keep pace with a nearly doubled treatment population will determine how quickly the approval translates into patients actually treated.